Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

Yuval Shaked, Urban Emmenegger, Shan Man, Dave Cervi, Francesco Bertolini, Yaacov Ben-David, Robert S. Kerbel

Research output: Contribution to journalArticle

Abstract

Low-dose metronomic chemotherapy is a promising therapeutic cancer treatment strategy thought to have an antiangiogenic basis. However, the advantages of reduced toxicity, increased efficacy in some cases, and ability to combine chemotherapy administered long term in this way with targeted therapies can be compromised by the empiricism associated with determining the optimum biologic dose (OBD). Using 4 distinct metronomic chemotherapy regimens in 4 different preclinical tumor models, including a hematologic malignancy, we established the OBD by determining the maximum efficacy associated with minimum or no toxicity. We then found each OBD to be strikingly correlated with the maximum reduction in viable peripheral blood circulating vascular endothelial growth factor receptor 2-positive (VEGFR-2+) endothelial precursors (CEPs). These results suggest that CEPs may serve as a pharmacodynamic biomarker to determine the OBD of metronomic chemotherapy regimens.

Original languageEnglish
Pages (from-to)3058-3061
Number of pages4
JournalBlood
Volume106
Issue number9
DOIs
Publication statusPublished - Nov 2005

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity'. Together they form a unique fingerprint.

  • Cite this